ReviewCureus2026
Pediatric Obesity: Diagnostic and Therapeutic Approaches in the Context of International Guidelines With a Focus on Polish Practice.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric obesity is a common chronic disease with serious long-term health consequences. This narrative review compares current international and national recommendations for the diagnosis and management of pediatric obesity. We focus on guidance from the American Academy of Pediatrics (AAP), the World Health Organization (WHO), the UK National Institute for Health and Care Excellence (NICE), and the Polish pediatric position statement, with reference to other relevant European and expert consensus documents. We also summarize key pathophysiological mechanisms relevant to clinical assessment, diagnostic work-up, and treatment selection. We highlight areas of consensus and clinically important differences, especially in diagnostic thresholds, risk stratification, and screening for obesity-related comorbidities. Across frameworks, family-based lifestyle and behavioral intervention remain fundamental components of care. Pharmacotherapy, particularly glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide and semaglutide, and metabolic/bariatric surgery are recommended as adjunctive options for carefully selected adolescents with severe obesity and significant comorbidities. In Poland, published reports and policy analyses suggest that implementation is often constrained by delayed access to specialist obesity services and structured lifestyle-behavioral support, as well as limited reimbursement for anti-obesity medications. As a result, escalation of care may occur late, even among adolescents who meet guideline-based criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.